Ovarian cancer remains the deadliest of gynecologic malignancies, and a newly published study reports that the secreted protein ANGPTL4 may play a central role in driving its spread. According to research published in Clinical and Experimental Medicine, ANGPTL4 was significantly upregulated in metastatic ovarian cancer tissues, and higher expression of the protein was associated with worse overall survival in patients.
The study, authored by Yinping Liu, Enci Dai, Rui Yang and colleagues with Wei Bao as senior author, set out to clarify the regulatory mechanism of ANGPTL4 in ovarian cancer progression. The researchers analyzed ANGPTL4 expression in ovarian cancer tissues and cell lines using high-throughput sequencing, immunohistochemistry and bioinformatics, and evaluated how expression levels correlated with patient prognosis.
Functionally, the team found that ANGPTL4 enhanced tumor cell migration and invasion in laboratory experiments.
The mechanistic findings trace a specific signaling pathway. According to the abstract, secreted ANGPTL4 was associated with activation of the Integrin β1/FAK/STAT3 signaling cascade. This activation subsequently upregulated ETV5, a transcription factor that then directly bound to the promoter of the CDH5 gene and activated its transcription.
The authors describe this as a novel ANGPTL4–Integrin β1–ETV5–CDH5 signaling axis through which ANGPTL4 promotes both tumor cell invasion and angiogenesis, the formation of new blood vessels that supply growing tumors.
ANGPTL4, or angiopoietin-like 4, is known to be highly expressed in several solid tumors, but its role in ovarian cancer metastasis had remained unclear prior to this investigation. The new findings position the protein as a potential link between metastatic behavior and angiogenic phenotypes in this disease.
The authors state that these findings provide a theoretical foundation for developing novel therapeutic strategies targeting ANGPTL4 in ovarian cancer. The authors state that these findings provide a theoretical foundation for developing novel therapeutic strategies targeting ANGPTL4 in ovarian cancer, though the study itself did not test therapeutic agents.
It is worth noting that the article was shared early as a peer-reviewed, accepted manuscript, a citable version that carries a permanent DOI but remains subject to further edits before the final Version of Record is published. The functional conclusions about metastasis rest on in vitro cell experiments and in vivo tumor burden measurements, and the clinical correlations come from tissue and prognosis analyses described in the abstract.
Nevertheless, the identification of an ETV5–CDH5-associated pathway downstream of ANGPTL4 adds a defined molecular chain to the growing map of processes that ovarian cancer cells appear to exploit during metastatic spread and blood vessel formation.
Subject of Research: The role of ANGPTL4 and the ETV5–CDH5 signaling axis in ovarian cancer metastasis and angiogenesis
Article Title: ANGPTL4 promotes metastatic and angiogenic phenotypes in ovarian cancer through an ETV5–CDH5-associated signaling axis
Article References: Liu, Y., Dai, E., Yang, R., Zhang, Y., Zhu, Y., Li, Y., Zhou, L., & Bao, W. (2026). ANGPTL4 promotes metastatic and angiogenic phenotypes in ovarian cancer through an ETV5–CDH5-associated signaling axis. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-026-02323-z
Image Credits: AI Generated
DOI: 10.1007/s10238-026-02323-z
Keywords: ovarian cancer, ANGPTL4, ETV5, CDH5, metastasis, angiogenesis, Integrin beta 1, FAK, STAT3, AKT signaling, MMP2, MMP9
News Source: Nathaniel Bowman. (October 28, 2026). Study Identifies ANGPTL4 Signaling Axis Driving Ovarian Cancer Invasion and Angiogenesis. Scienmag.
